Pyxis Oncology, Inc. (PYXS) stock
Close on Nov 12, 2026Market cap $131.78MP/E –Yield –
Pyxis Oncology, Inc. saw revenue fall 14.2% to $13.86M over fiscal 2025. Free cash flow was -$63.51M. At the latest close the market valued the company at $131.78M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $131.78M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.19
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $13.86M
- Net income
- -$86.71M
- EPS, diluted
- -$1.30
- Free cash flow
- -$63.51M
- Book value per share
- $0.49
- Diluted shares
- 84M
Trading
- Next earnings
- Mar 22, 2027 (estimated, before the open)
- Previous close
- $1.64
- Open
- $1.62
- Day's range
- $1.52 – $1.63
- Volume
- 1,003,404
- Average volume (20 days)
- 799,204
- Beta (5 years)
- 1.62
- 52-week range
- $1.03 – $5.55
- RSI (14 days)
- 36.7
- Volatility (1 year)
- 123.8%
- Relative volume
- 0.58×
- WACC
- 13.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PYXS | S&P 500 | Difference | PYXS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -21.4% | -2.7% | −18.7 pts | ||
| 3 months | -50.3% | -1.7% | −48.6 pts | ||
| Year to date | +37.4% | +11.9% | +25.5 pts | ||
| 1 year | -63.8% | +12.0% | −75.8 pts | ||
| 3 years | +3.3% | +78.2% | −74.9 pts | +1.1% | +21.2% |
| 5 years | -86.6% | +73.2% | −159.9 pts | -33.1% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pyxis Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
About Pyxis Oncology
Pharmaceutical Preparations
Pyxis Oncology is a clinical-stage biopharmaceutical company that develops targeted cancer therapies for individuals with difficult-to-treat solid tumors. The company focuses primarily on treating recurrent and metastatic head and neck squamous cell carcinoma. Its lead investigational product candidate is micvotabart pelidotin, an antibody-drug conjugate designed to target an extracellular matrix protein variant within tumor microenvironments. The company evaluates this drug candidate both as a single-agent monotherapy and in combination with other cancer immunotherapies across various solid tumor types, including breast, cervical, and gastric cancers. It also maintains technology platforms for antibody discovery and conjugate design. The target population consists of cancer patients with advanced solid malignancies who require further intervention after initial systemic therapies.
Company profile, executives and historyPyxis Oncology stock: common questions
What is Pyxis Oncology's stock price?
PYXS closed at $1.58 on Nov 12, 2026, down 3.66% on the day. Over the past 52 weeks it traded between $1.03 and $5.55.
What is Pyxis Oncology's market cap?
Pyxis Oncology was worth $131.78M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PYXS's P/E ratio?
Pyxis Oncology lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.30), so it has no meaningful P/E ratio.
How much revenue does Pyxis Oncology make?
Pyxis Oncology reported revenue of $13.86M for fiscal 2025, down 14.2% from a year earlier.
Does Pyxis Oncology pay a dividend?
No. Pyxis Oncology has not paid a cash dividend over the last twelve months.
When does Pyxis Oncology report earnings next?
Pyxis Oncology is expected to report Q4 FY2026 results on Mar 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PYXS stock performed over the past year?
Including dividends, PYXS returned -63.8% over the past year, against +12.0% for the S&P 500.
How many PYXS shares are sold short?
5M shares were sold short at the latest FINRA report, 6.81% of the float, or 5.8 days of average trading volume.
Who are Pyxis Oncology's competitors?
Companies most similar to Pyxis Oncology by business, industry and size include CBIO, CTMX, PRLD, ZNTL, WHWK.
See a number that looks wrong?